SCHEMBL6486897

SCHEMBL6486897

COc1ccc(-c2nc(COc3cccc4cc(NS(=O)(=O)C(F)(F)F)ccc34)cs2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.44
TP53 P04637 1/20 0.44
CYSLTR2 Q9NS75 1/20 0.44
CYSLTR1 Q9Y271 1/20 0.44
ALDH1A1 P00352 5/20 0.44
HPGD P15428 3/20 0.44
HSD17B10 Q99714 1/20 0.44
KDM4E B2RXH2 3/20 0.43
EGFR P00533 1/20 0.41
ERBB2 P04626 1/20 0.41
EPHA2 P29317 1/20 0.41
KDR P35968 1/20 0.41
EPHB4 P54760 1/20 0.41
IDO1 P14902 1/20 0.41
TDO2 P48775 1/20 0.41
LMNA P02545 1/20 0.40
CNR1 P21554 1/20 0.40
HTT P42858 1/20 0.40
GPR55 Q9Y2T6 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6485920 0.92 SHMT2 (0.44) MAPTTP53CYSLTR2CYSLTR1ALDH1A1
SCHEMBL6485303 0.91 CYSLTR2 (0.45) MAPTTP53CYSLTR2CYSLTR1EGFR
SCHEMBL6476503 0.90 CYSLTR2 (0.48) MAPTCYSLTR2CYSLTR1ALDH1A1HPGD
SCHEMBL6475810 0.90 CYSLTR2 (0.42) MAPTTP53CYSLTR2CYSLTR1EGFR
SCHEMBL6526673 0.90 EGFR (0.46) MAPTTP53CYSLTR2CYSLTR1KDM4E
SCHEMBL6487034 0.90 SCN9A (0.45) MAPTTP53CYSLTR2CYSLTR1EGFR
SCHEMBL9721986 0.88 CYSLTR2 (0.56) MAPTTP53CYSLTR2CYSLTR1ALDH1A1
SCHEMBL6477804 0.86 CYSLTR2 (0.42) CYSLTR2CYSLTR1EGFRERBB2EPHA2
SCHEMBL6477257 0.86 IDO1 (0.43) MAPTCYSLTR2CYSLTR1ALDH1A1HPGD
SCHEMBL6477943 0.85 CYSLTR2 (0.41) TP53CYSLTR2CYSLTR1EGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030216442-A1 Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus WYETH 2003-11-20 US claimed
US-6933322-B2 Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus WYETH (US) 2005-08-23 US disclosed
US-20030216442-A1 Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus WYETH 2003-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216442-A1 Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus INSR, GPR119, SLC5A1 MAPT 4257/4885TP53 2971/4885CYSLTR2 4879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.